Eli Lilly is expanding its AI drug discovery footprint through a multibillion-dollar commercialization and development deal with Insilico Medicine. Under terms disclosed by Insilico, Lilly will pay $115 million up front and could deliver up to $2.75 billion in milestone payments, with additional tiered royalties tied to future sales. Lilly’s Insilico collaboration is designed to develop and commercialize experimental oral therapeutics in preclinical development across multiple therapeutic areas. The expansion follows Lilly’s earlier AI-focused licensing and collaboration efforts and underscores the company’s push to diversify pipeline access while maintaining development velocity. For Insilico, the deal effectively converts AI-discovery output into a late-binding pipeline bet where development, regulatory, and commercial milestones drive most of the value—reinforcing the growing shift toward pharma-backed, AI-to-product licensing structures.